Profile data is unavailable for this security.
About the company
Marksans Pharma Limited is an India-based company, which is engaged in research, manufacturing and marketing of generic pharmaceutical formulations in the global markets. The Company's product portfolio spreads various therapeutic segments of cardiovascular system (CVS), central nervous system (CNS), antidiabetic, pain management, cough and cold, gastroenterological, and anti-allergies. Its product portfolio includes tablets (plain, enteric-coated and film-coated), hard capsules, soft gelatin capsules, oral liquids and ointments. Its consumer self-care products (over the counter) include pain management, upper respiratory, digestive health, vitamins minerals and supplements (VMS) and skin care products. The Company's prescription - Rx therapeutic segments include CVS, CNS, oncology, anti-diabetics and anti-biotic. Its end consumers include retail chains, pharmacy stores, hospitals and institutions. It has manufacturing facilities in India, the United Kingdom and the United States.
- Revenue in INR (TTM)22.68bn
- Net income in INR3.34bn
- Incorporated1992
- Employees2.00k
- LocationMarksans Pharma Ltd21 Lotus Business Park, Off New Link Road,, Andheri (W)MUMBAI 400053IndiaIND
- Phone+91 2 240012000
- Fax+91 2 240012099
- Websitehttp://www.marksanspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Orchid Pharma Ltd | 8.81bn | 1.12bn | 71.16bn | 872.00 | 61.31 | -- | 48.56 | 8.08 | 22.89 | 22.89 | 180.65 | -- | -- | -- | -- | 10,101,540.00 | -- | -0.9734 | -- | -1.40 | 40.67 | 40.74 | 12.78 | -2.40 | -- | 6.08 | -- | -- | 23.05 | 6.43 | 73.59 | 5.84 | 57.79 | -- |
| Sun Pharma Advanced Research Co Ltd | 684.05m | -3.89bn | 71.31bn | 409.00 | -- | -- | -- | 104.25 | -11.97 | -11.97 | 2.11 | -- | -- | -- | -- | 1,672,501.00 | -- | -61.70 | -- | -119.31 | 59.81 | 74.49 | -568.24 | -163.40 | -- | -208.33 | -- | -- | -68.36 | -16.21 | -73.96 | -- | 15.40 | -- |
| Procter & Gamble Health Ltd | 11.51bn | 2.01bn | 85.00bn | 1.41k | 42.31 | 15.79 | 37.22 | 7.38 | 121.01 | 121.01 | 693.20 | 324.24 | 1.21 | 2.71 | 11.45 | -- | 21.21 | -- | 29.28 | -- | 71.29 | -- | 17.46 | -- | 1.90 | 386.94 | 0.0175 | -- | -6.37 | -- | -12.42 | -- | -- | -- |
| Shilpa Medicare Ltd | 11.84bn | 447.57m | 88.20bn | 931.00 | 180.56 | -- | 57.62 | 7.45 | 5.00 | 5.00 | 133.55 | -- | -- | -- | -- | 12,716,850.00 | -- | 2.84 | -- | 3.65 | 65.19 | 60.08 | 3.79 | 7.03 | -- | 1.56 | -- | 10.76 | 9.66 | 9.44 | 198.15 | -22.26 | -9.26 | -- |
| Blue Jet Healthcare Ltd | 6.95bn | 1.57bn | 91.16bn | 447.00 | 57.90 | -- | 49.83 | 13.12 | 9.08 | 9.08 | 40.07 | -- | -- | -- | -- | 15,547,110.00 | -- | -- | -- | -- | 55.54 | -- | 22.65 | -- | -- | 124.37 | -- | -- | -1.30 | -- | 2.33 | -- | -- | -- |
| F D C Ltd | 20.45bn | 3.14bn | 94.82bn | 6.66k | 30.31 | -- | 26.67 | 4.64 | 19.21 | 19.21 | 124.56 | -- | -- | -- | -- | 3,070,786.00 | -- | 12.05 | -- | 13.73 | 65.55 | 61.54 | 15.37 | 15.85 | -- | 75.15 | -- | 1.09 | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
| Strides Pharma Science Ltd | 42.09bn | -475.19m | 125.59bn | 3.07k | -- | -- | 90.91 | 2.98 | -5.44 | 0.4871 | 460.14 | -- | -- | -- | -- | 13,731,270.00 | -- | -1.68 | -- | -2.97 | 60.18 | 51.39 | -1.68 | -3.36 | -- | 1.24 | -- | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
| Marksans Pharma Ltd | 22.68bn | 3.34bn | 127.44bn | 2.00k | 38.14 | -- | 30.74 | 5.62 | 7.37 | 7.37 | 50.09 | -- | -- | -- | -- | 11,339,960.00 | -- | 14.62 | -- | 18.52 | 53.39 | 50.52 | 14.71 | 14.03 | -- | 32.19 | -- | 6.17 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
| Granules India Ltd | 47.01bn | 4.92bn | 132.68bn | 4.12k | 26.98 | -- | 18.87 | 2.82 | 20.29 | 20.29 | 193.87 | -- | -- | -- | -- | 11,403,970.00 | -- | 10.68 | -- | 16.18 | 56.89 | 48.83 | 10.47 | 11.82 | -- | 6.95 | -- | 8.96 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
| Akums Drugs and Pharmaceuticals Ltd | -100.00bn | -100.00bn | 133.05bn | 7.39k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.32 | -- | -104.25 | -- | -- | -- |
| Wockhardt Ltd | 28.93bn | -3.43bn | 146.94bn | 2.39k | -- | -- | -- | 5.08 | -23.75 | -23.75 | 199.60 | -- | -- | -- | -- | 12,084,380.00 | -- | -4.56 | -- | -8.29 | 58.66 | 55.26 | -12.17 | -12.70 | -- | 0.0764 | -- | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
| Caplin Point Laboratories Ltd | 17.58bn | 4.78bn | 149.40bn | 859.00 | 31.36 | -- | 27.66 | 8.50 | 62.67 | 62.67 | 230.62 | -- | -- | -- | -- | 20,462,630.00 | -- | 19.83 | -- | 22.82 | 58.41 | 53.38 | 27.43 | 25.39 | -- | 1,525.59 | -- | 9.06 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 17.84 |
| Glenmark Life Sciences Ltd | 22.93bn | 4.47bn | 155.81bn | 2.01k | 34.93 | -- | 31.03 | 6.79 | 36.41 | 36.41 | 186.81 | -- | -- | -- | -- | 11,387,190.00 | -- | 18.28 | -- | 29.99 | 54.58 | 53.40 | 19.49 | 20.23 | -- | 389.45 | -- | 26.37 | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Neuland Laboratories Ltd. | 16.35bn | 3.36bn | 163.08bn | 1.65k | 48.53 | -- | 40.93 | 9.97 | 261.94 | 261.94 | 1,274.50 | -- | -- | -- | -- | 9,922,259.00 | -- | 9.25 | -- | 12.71 | 53.32 | 47.81 | 20.55 | 11.99 | -- | 29.52 | -- | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Sanofi India Ltd | 23.83bn | 4.30bn | 164.60bn | 2.17k | 38.30 | 24.04 | 35.17 | 6.91 | 186.62 | 229.86 | 1,034.61 | 297.26 | 1.67 | 2.73 | 15.60 | 10,960,440.00 | 30.08 | 22.42 | 57.55 | 30.21 | 55.95 | 55.52 | 18.04 | 21.03 | 0.8140 | 435.86 | 0.0313 | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Astrazeneca Pharma India Ltd | 13.88bn | 958.59m | 167.89bn | 940.00 | 175.14 | -- | 151.37 | 12.10 | 38.34 | 38.34 | 555.18 | -- | -- | -- | -- | 14,761,520.00 | -- | 11.78 | -- | 19.62 | 48.51 | 54.64 | 6.91 | 10.27 | -- | 121.25 | -- | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
Data as of Sep 20 2024. Currency figures normalised to Marksans Pharma Ltd's reporting currency: Indian Rupee INR
5.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Aug 2024 | 8.35m | 1.84% |
| Dimensional Fund Advisors LPas of 05 Sep 2024 | 5.54m | 1.22% |
| Kotak Mahindra Asset Management Co. Ltd.as of 31 Aug 2024 | 3.42m | 0.76% |
| SSgA Funds Management, Inc.as of 05 Sep 2024 | 2.76m | 0.61% |
| BlackRock Fund Advisorsas of 05 Sep 2024 | 2.11m | 0.47% |
| Old Bridge Asset Management Pvt Ltd.as of 31 Aug 2024 | 1.64m | 0.36% |
| Bandhan Asset Management Co. Ltd.as of 31 Aug 2024 | 903.94k | 0.20% |
| BlackRock Advisors (UK) Ltd.as of 05 Sep 2024 | 726.17k | 0.16% |
| Fiduciary Management, Inc.as of 30 Jun 2024 | 662.00k | 0.15% |
| Templeton Investment Counsel LLCas of 30 Jun 2024 | 546.83k | 0.12% |
More ▼
Data from 30 Jun 2024 - 31 Aug 2024Source: FactSet Research Systems Inc.
